An EvoNexus Incubator Company
toSense™ is developing the CoVa™ Monitoring System, featuring a novel body-worn Sensor for at-home patients with chronic illnesses, such as congestive heart failure (CHF), chronic obstructive pulmonary disease, hypertension, and renal failure. Worn like a conventional necklace for just minutes each day, the Sensor measures thoracic bioimpedance and electrocardiogram waveforms, and from these calculates a thoracic impedance, heart rate, heart rate variability, and respiration rate. Once the Sensor has completed its measurements, information is sent wireless via Bluetooth® to a Gateway. The Gateway forwards the information to Web-based system for remote monitoring by a medical professional.
The same hardware, augmented with next-generation versions of firmware, will measure additional vital signs and hemodynamic properties such as stroke volume and cardiac output.
One goal of the CoVa™ Monitoring System is to make at-home monitoring of cardiopulmonary parameters for heart failure patients as simple as glucose monitoring for diabetics. Current solutions are relegated to technologies such as weight scales, which are insensitive to physiological parameters and are unable to characterize early onset of CHF. Weight is a late indicator of a potential heart failure event. Clinical trails have shown that measurements such as fluid level, stroke volume, and cardiac output provide an early indication of a potential heart failure event. With the CoVa™ Monitoring System, this information is available remotely to medical professionals.
Received FDA approval for heart monitoring necklace in May 2015.
Acquired by Baxter International in 2020.